Clinical Trial

Ventricular Tachycardia:A Registry Study

Recruiting
View on ClinicalTrials.gov →
Summary
Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-30
critical Primary endpoint(s) modified 2026-07-30
notable Enrollment reduced: 1500 -> 1000 participants 2026-07-30
Trial Details
NCT Number NCT07149701
Lead Sponsor Beijing Anzhen Hospital
Conditions Ventricular Tachycardia (VT), Structural Heart Disease
Enrollment 1,000 participants
Start Date 2025-10-14
Primary Completion 2029-09-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29